Literature DB >> 25841922

Risk factors for developing hepatocellular carcinoma in Egypt.

Ashraf Omar1, Ghassan K Abou-Alfa2, Ahmed Khairy1, Heba Omar1.   

Abstract

Hepatocellular carcinoma (HCC) is a common disorder worldwide and ranks 2nd and 6th most common cancer among men and women in Egypt. HCC has a rising incidence in Egypt mostly due to high prevalence of viral hepatitis and its complications. Proper management requires the interaction of multidisciplinary HCC clinic to choose the most appropriate plan. The different modalities of treatment include resection (surgery or transplantation), local ablation, chemoembolization, radioembolization and molecular targeted therapies. This paper summarizes both the environmental and host related risk factors of HCC in Egypt including well-established risk factors such as hepatitis virus infection, aflatoxin, as well as possible risk factors.

Entities:  

Keywords:  Egypt; Hepatocellular carcinoma (HCC); epidemiology; risk factors

Year:  2013        PMID: 25841922     DOI: 10.3978/j.issn.2304-3865.2013.11.07

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN: 2304-3865


  10 in total

1.  Wide Sexual Dimorphism of Hepatocellular Carcinoma Presentation in Algeria.

Authors:  Yazid Chikhi; Salima Cheraitia; Rachid Ould Gougam; Fadila Lounes; Chahrazed Zemmouchi; Nassila Belal; Maroua Bendaoud; Sonia Ait Younes; Aicha Bensalem; Saadi Berkane; Hocine Asselah; Pascal Pineau; Mustapha Lahcene
Journal:  Gastrointest Tumors       Date:  2019-08-30

2.  Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression.

Authors:  Neven A Hagag; Yasser B M Ali; Ahmed A Elsharawy; Roba M Talaat
Journal:  J Gastrointest Cancer       Date:  2020-03

3.  Liver Disease Outcomes after Sustained Virological Response in Patients with Chronic Hepatitis C Infection Treated with Generic Direct-Acting Antivirals.

Authors:  Ekram W Abd El-Wahab; Waleed M Abd Elgawad; Mohamed S Abdelaziz; Ashraf I Mikheal; Hanan Z Shatat
Journal:  Am J Trop Med Hyg       Date:  2022-02-28       Impact factor: 3.707

4.  Study of Dickkopf-1 (DKK-1) in patients with chronic viral hepatitis C-related liver cirrhosis with and without hepatocellular carcinoma.

Authors:  Mona Kamal Eldeeb; Gehan Mahmoud Magour; Rania Nabil Bedair; Mohammed Mahmoud Shamseya; Mennatallah Abdelfattah Hammouda
Journal:  Clin Exp Hepatol       Date:  2020-05-29

5.  Inflammasome Genes' Polymorphisms in Egyptian Chronic Hepatitis C Patients: Influence on Vulnerability to Infection and Response to Treatment.

Authors:  Shady Z K Estfanous; Sahar A Ali; Sameh M Seif; Sameh H A Soror; Dalia H A Abdelaziz
Journal:  Mediators Inflamm       Date:  2019-01-09       Impact factor: 4.711

Review 6.  Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures.

Authors:  Reem Ezzat; Mohamed Eltabbakh; Mohamed El Kassas
Journal:  World J Gastrointest Oncol       Date:  2021-12-15

7.  Diagnostic and Prognostic Value of Talin-1 and Midkine as Tumor Markers in Hepatocellular Carcinoma in Egyptian Patients

Authors:  Aya H Mashaly; Rokiah Anwar; Mohamed A Ebrahim; Laila A Eissa; Mamdouh M El Shishtawy
Journal:  Asian Pac J Cancer Prev       Date:  2018-06-25

8.  XRCC1 Gene Polymorphism Increases the Risk of Hepatocellular Carcinoma in Egyptian Population.

Authors:  Mary Naguib; Mohamed M Helwa; Mohammed M Soliman; Mohamed Abdel-Samiee; Ashraf M Eljaky; Osama Hammam; Hassan Zaghla; Eman Abdelsameea
Journal:  Asian Pac J Cancer Prev       Date:  2020-04-01

9.  Manuka honey enhanced sensitivity of HepG2, hepatocellular carcinoma cells, for Doxorubicin and induced apoptosis through inhibition of Wnt/β-catenin and ERK1/2.

Authors:  Heba R Al Refaey; Al-Sayeda A Newairy; Mayssaa M Wahby; Chris Albanese; Mohamed Elkewedi; Muhammad Umer Choudhry; Ahmed S Sultan
Journal:  Biol Res       Date:  2021-05-28       Impact factor: 5.612

10.  Molecular and genetic markers in hepatocellular carcinoma: In silico analysis to clinical validation (current limitations and future promises).

Authors:  Sarah El-Nakeep
Journal:  World J Gastrointest Pathophysiol       Date:  2022-01-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.